Regeneron’s COVID-19 Outpatient Trial Prospectively Demonstrates that REGN-COV2 Antibody Cocktail Significantly Reduced Virus Levels and Need for Further Medical Attention
The Pharma Data
OCTOBER 28, 2020
In the overall patient group with detectable virus at baseline, the average daily reduction in viral load through day 7 was a 0.36 Senior Vice President and Head of Global Clinical Development at Regeneron. There was a 1.08 log10 copies/mL greater reduction with REGN-COV2 compared to placebo (combined dose groups; p=0.0003). .
Let's personalize your content